Dr. Jarvis and Mike Verkest were at the EMS Expo in Atlanta. We recorded some interviews from the FlightbridgeED booth on the exhibitor floor and then discussed them when Mike stopped by Casa Jarvis in Austin a bit later. There was so much goodness that we broke it up into two different episodes to keep these at a reasonable length.

Ketamine has been getting a lot of attention recently in the media. It's probably safe to say it’s had a bad year. We like ketamine. We felt bad it’s been having a rough year so we wanted to do something that would lift its spirits. Fortunately, Dr. David Barbic and his colleagues from Vancouver, BC published a wonderful, randomized trial comparing ketamine to a combination of haloperidol plus midazolam for undifferentiated agitation in the ED. This was the amazingly titled RACKED trial (Rapid Agitation Control with Ketamine in the ED). It has direct and important implications for EMS and is something all emergency providers should know about. Dr. Jarvis reviews the trial and then invites Dr. Barbic himself on the show to discuss this study. If you like the show, please give us a like on YouTube and a 5-star rating wherever you get your podcasts.

Mike and Jeff meet to discuss some airway papers from the National Emergency Airway Registry (NEAR) and float some merch ideas. If you like the show, please give us a like on YouTube and a 5-star rating wherever you get your podcasts. Drop your questions/comments/suggestions for future pods at: [email protected] or @DrJeffJarvis.

In this episode, Dr. Jarvis discusses a paper that is hot off the press, and he’s excited to discuss it. The good folks up in Seattle, WA, and the Seattle FD looked at their cardiac arrest survival rates as a function of the number of intubation attempts needed to secure the airway. Results from this trial might help explain the 2.9% improved survival with King LT vs ETI that we saw in the PART trial. Join us to hear all the juicy details. As always, if you like the pod, give us a 5-star rating wherever you get your pods. If you have any questions, drop us a note: [email protected] or @DrJeffJarvis. You can also follow the pod on Twitter @EMSLighthouseProject.

Every other year, board-certified EMS physicians must take an open book quiz over 20-25 papers felt by the American Board of Emergency Medicine (ABEM) to be something all EMS physicians should know. Dr. Jarvis and Dr. Casey Patrick (@cpatrick_89) from Montgomery County Health District EMS gave a lecture reviewing the 2020 ABEM EMS LLSA articles at the Texas Chapter of NAEMSP meeting. We got together right after our lecture to record this podcast, going over these articles. Join us from the Cavalier Room at the Historic Menger Hotel (@mengerhotel) in downtown San Antonio, literally next door to the Alamo.

Ketamine is a wonder drug. Ketamine is a tool of systemic racism. Ketamine is impossible to overdose. Ketamine is an inappropriate drug used for inappropriate purposes. So much controversy. What should we believe? When in doubt, follow the data. Dr. Jeff Jarvis reviews a very timely paper just released in Annals of Emergency Medicine using the 2019 Data Collaborative data set that aims to describe the characteristics of patients getting ketamine as well as the potential deaths associated with it. As a bonus, Drs. Remle Crowe and Brent Myers join Dr. Jarvis for an interview about their paper and the controversies surrounding ketamine use.

What is the impact of on-scene resuscitation vs intra-arrest transport on outcomes? Could the differences in first-pass success between ETI and King LT have accounted for the differences in outcome in the PART trial? How about differences in compression interruptions? In this episode recorded on the road in Bend, Oregon, Dr. Jarvis reviews three new papers addressing these questions. He then interviewed Petar and Amber Hossick about how Bend Fire Rescue has implemented tenets of improvement science to impact survival in their community.

We saw the amazing performance of Pfizer and Moderna's two mRNA COVID vaccines in their RCTs. As encouraging as trial performance is, we always want to know how those numbers hold up under large-scale, real-world pragmatic conditions. Well, we now have three new pieces of information on that. And, for the cherry on top, we get evidence of performance against asymptomatic infection! Dr. Jarvis does a quick review of the latest evidence on vaccine performance.

December 4, 2001. A bad day, indeed. That’s the day the FDA issued a black box warning for droperidol, citing evidence of QT prolongation, Torsades de Pointes, and death. This was a surprise warning because droperidol had been extensively used by emergency medicine and anesthesiology for decades without apparent problems. Since this bad day, we’ve essentially been without droperidol. Fortunately, it’s back! Before we use it again, we should look at what got this drug on the FDA’s radar. Dr. Jarvis reviews the literature about the “evidence” behind the warning and describes how his systems will be bringing droperidol back into practice.

The FDA just granted EUA for the Johnson and Johnson vaccine against COVID. This is a big deal because it is a one-shot vaccination that is much more stable than the two mRNA vaccines. Dr. Jarvis provides a quick overview of the data submitted to the FDA for approval.